Multiple myeloma

Clinical practice guidelines in oncology™

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Raymond L. Comenzo, Carlos M. De Castro, Benjamin Djulbegovic, Sherif Farag, Carol Ann Huff, Ruby Meredith, Jeffrey Schriber, Dennis Shrieve, Seema Singhal, Mitchell R. Smith, Keith Stockerl-Goldstein, Julie M. Vose, Donna Weber, Joachim Yahalom, Furhan Yunus

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Although multiple myeloma is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. These guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.

Original languageEnglish
Pages (from-to)118-147
Number of pages30
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume5
Issue number2
StatePublished - Feb 2007
Externally publishedYes

Fingerprint

Multiple Myeloma
Practice Guidelines
Therapeutics
Clinical Protocols
Radiotherapy
Quality of Life
Guidelines
Drug Therapy

Keywords

  • C-reactive protein
  • Combination chemotherapy
  • Cytogenetics
  • Immunomodulatory drugs
  • Multiple myeloma
  • NCCN Clinical Practice Guidelines
  • Primary amyloidosis
  • Proteosome inhibitor
  • Stem cell transplant
  • Waldenström's monoclonal protein

ASJC Scopus subject areas

  • Oncology

Cite this

Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., Comenzo, R. L., ... Yunus, F. (2007). Multiple myeloma: Clinical practice guidelines in oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 5(2), 118-147.

Multiple myeloma : Clinical practice guidelines in oncology™. / Anderson, Kenneth C.; Alsina, Melissa; Bensinger, William; Biermann, J. Sybil; Chanan-Khan, Asher; Comenzo, Raymond L.; De Castro, Carlos M.; Djulbegovic, Benjamin; Farag, Sherif; Huff, Carol Ann; Meredith, Ruby; Schriber, Jeffrey; Shrieve, Dennis; Singhal, Seema; Smith, Mitchell R.; Stockerl-Goldstein, Keith; Vose, Julie M.; Weber, Donna; Yahalom, Joachim; Yunus, Furhan.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 5, No. 2, 02.2007, p. 118-147.

Research output: Contribution to journalArticle

Anderson, KC, Alsina, M, Bensinger, W, Biermann, JS, Chanan-Khan, A, Comenzo, RL, De Castro, CM, Djulbegovic, B, Farag, S, Huff, CA, Meredith, R, Schriber, J, Shrieve, D, Singhal, S, Smith, MR, Stockerl-Goldstein, K, Vose, JM, Weber, D, Yahalom, J & Yunus, F 2007, 'Multiple myeloma: Clinical practice guidelines in oncology™', JNCCN Journal of the National Comprehensive Cancer Network, vol. 5, no. 2, pp. 118-147.
Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL et al. Multiple myeloma: Clinical practice guidelines in oncology™. JNCCN Journal of the National Comprehensive Cancer Network. 2007 Feb;5(2):118-147.
Anderson, Kenneth C. ; Alsina, Melissa ; Bensinger, William ; Biermann, J. Sybil ; Chanan-Khan, Asher ; Comenzo, Raymond L. ; De Castro, Carlos M. ; Djulbegovic, Benjamin ; Farag, Sherif ; Huff, Carol Ann ; Meredith, Ruby ; Schriber, Jeffrey ; Shrieve, Dennis ; Singhal, Seema ; Smith, Mitchell R. ; Stockerl-Goldstein, Keith ; Vose, Julie M. ; Weber, Donna ; Yahalom, Joachim ; Yunus, Furhan. / Multiple myeloma : Clinical practice guidelines in oncology™. In: JNCCN Journal of the National Comprehensive Cancer Network. 2007 ; Vol. 5, No. 2. pp. 118-147.
@article{db52b79604504efcbdabfdffb6fbda07,
title = "Multiple myeloma: Clinical practice guidelines in oncology™",
abstract = "Although multiple myeloma is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. These guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.",
keywords = "C-reactive protein, Combination chemotherapy, Cytogenetics, Immunomodulatory drugs, Multiple myeloma, NCCN Clinical Practice Guidelines, Primary amyloidosis, Proteosome inhibitor, Stem cell transplant, Waldenstr{\"o}m's monoclonal protein",
author = "Anderson, {Kenneth C.} and Melissa Alsina and William Bensinger and Biermann, {J. Sybil} and Asher Chanan-Khan and Comenzo, {Raymond L.} and {De Castro}, {Carlos M.} and Benjamin Djulbegovic and Sherif Farag and Huff, {Carol Ann} and Ruby Meredith and Jeffrey Schriber and Dennis Shrieve and Seema Singhal and Smith, {Mitchell R.} and Keith Stockerl-Goldstein and Vose, {Julie M.} and Donna Weber and Joachim Yahalom and Furhan Yunus",
year = "2007",
month = "2",
language = "English",
volume = "5",
pages = "118--147",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "2",

}

TY - JOUR

T1 - Multiple myeloma

T2 - Clinical practice guidelines in oncology™

AU - Anderson, Kenneth C.

AU - Alsina, Melissa

AU - Bensinger, William

AU - Biermann, J. Sybil

AU - Chanan-Khan, Asher

AU - Comenzo, Raymond L.

AU - De Castro, Carlos M.

AU - Djulbegovic, Benjamin

AU - Farag, Sherif

AU - Huff, Carol Ann

AU - Meredith, Ruby

AU - Schriber, Jeffrey

AU - Shrieve, Dennis

AU - Singhal, Seema

AU - Smith, Mitchell R.

AU - Stockerl-Goldstein, Keith

AU - Vose, Julie M.

AU - Weber, Donna

AU - Yahalom, Joachim

AU - Yunus, Furhan

PY - 2007/2

Y1 - 2007/2

N2 - Although multiple myeloma is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. These guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.

AB - Although multiple myeloma is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. These guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.

KW - C-reactive protein

KW - Combination chemotherapy

KW - Cytogenetics

KW - Immunomodulatory drugs

KW - Multiple myeloma

KW - NCCN Clinical Practice Guidelines

KW - Primary amyloidosis

KW - Proteosome inhibitor

KW - Stem cell transplant

KW - Waldenström's monoclonal protein

UR - http://www.scopus.com/inward/record.url?scp=33947193435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947193435&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 118

EP - 147

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 2

ER -